iBio, Inc. IBIO 深 滬
等待開盤 07-21 09:30:00 美东时间
0.731
+0.001
+0.14%
華盛通- 最 高0.7339
- 今 開0.7268
- 成交量 68.21万股
- 最 低 0.7159
- 昨 收 0.73
- 總市值 1207.56万
- 52周最高 6.8908
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.6358
- 委 比 -88.56%
- 總股本 1651.93万
- 歷史最高 17400.00
- 量 比 1.19
- 振 幅 2.47%
- 歷史最低 0.6358
- 每 手 1
- 風險率 1.25%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Intelligent Bio Solutions Accelerates Global Growth with SmarTest® Patch Agreement, Reinforces U.S. Expansion Path as FDA Approval Remains a Strategic Priority
Intelligent Bio Solutions Inc. (INBS) has entered a global distribution agreement with SMARTOX to launch the SmarTest Patch for drug detection in international markets beyond the U.S. and Canada. This collaboration strengthens INBS's position as a leader in non-invasive drug testing solutions, particularly in the justice and rehabilitation sectors. The SmarTest Patch enables continuous sweat-based drug detection over extended periods, complementi...
07-16 12:30
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
I-Mab announced the publication of first-in-human monotherapy data for givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, in *Clinical Cancer Research*. The study showed givastomig achieved an objective response rate (ORR) of 16-18% in heavily pretreated Claudin 18.2-positive gastric cancer patients, with a favorable safety profile. The findings support its development in combination with nivolumab and chemotherapy for first-line treatment o...
06-30 20:01
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
Chardan Capital Maintains Buy on iBio, Maintains $5 Price Target
Chardan Capital analyst Keay Nakae maintains iBio (NASDAQ:IBIO) with a Buy and maintains $5 price target.
06-25 20:34
Intelligent Bio Solutions and Spjotgard Drive Rapid Adoption of Fingerprint Drug Testing Across Scandinavia
<p>INBS, a medical technology company, has successfully partnered with Spjotgard, a distributor in the Scandinavian market, to expand the adoption of its fingerprint drug screening technology across Sweden, Norway, Denmark, and Finland. Spjotgard, founded in 2021, has positioned INBS' technology as its flagship solution due to rising demand for hygienic, non-invasive drug testing methods. The system is increasingly favored in safety-critical indu...
06-25 12:30
iBio Advances Obesity Care with Antibody Therapies
An announcement from Ibio ( ($IBIO) ) is now available. iBio, Inc. has updated ...
06-24 20:14
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
iBio announced preclinical data showing its engineered amylin receptor agonist antibody reduced acute food intake by 60% in obese mice, comparable to a DACRA peptide. This antibody selectively activates the amylin receptor, potentially offering better tolerability and efficacy than dual agonists. iBio's AI platform enables precise targeting, addressing limitations of current obesity treatments. The findings highlight antibody-based agonists as pr...
06-24 11:00
ibio Announces It Will Host Conference Call On Tuesday, June 24, At 8:30 A.M. EST To Review Its Latest Advances In Obesity And Cardiometabolic Disease Treatments And Announce A Third Target In The Astralbio Collaboration In Addition To Myostatin And Activin E
Review of promising Myostatin and Activin E antibody dataiBio to announce 3rd target in Astral Bio CollaborationConference call Tuesday, June 24 at 8:30 a.m. ETiBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of
06-24 04:17
iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
iBio, Inc. will host a conference call on June 24 to discuss advances in obesity and cardiometabolic disease treatments, announce a third target in the AstralBio Collaboration, and present new data on Myostatin (IBIO-600), Activin E, and other therapies. The call will highlight iBio's AI-driven antibody development for better efficacy and tolerability. A replay will be available on their website for 60 days.
06-23 20:15
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
iBio announces naming of IBIO-610 as development candidate for its Activin E antibody targeting obesity and cardiometabolic diseases. The company initiates a non-human primate study to evaluate pharmacokinetics and efficacy in obese, elderly NHPs. Preclinical data in mice show up to 8.9% body weight loss and enhanced fat-selective weight loss when combined with GLP-1 therapy. Results will be presented at ADA 2023.
06-16 11:00
